Blockade of the CXXC5‐Dvl PPI as a strategy for the treatment of metabolic diseases was further supported by the similar physiological improvement of metabolic abnormalities in both Cxxc5−/− mice and KY19334‐treated Cxxc5+/+ mice fed an HFD. This evidence concerns the gene CXXC5 and metabolic disease.